5 Signs and Symptoms of Geographic Atrophy

You use your eyes just about every waking moment, so you might assume that if something were wrong with your vision, you’d notice. And yet, that isn’t always the case. Many eye diseases, such as geographic atrophy (GA), can progress so stealthily — and with so few symptoms — that it can take some time before you’re aware anything is wrong.
Until 2023, there was no way to treat geographic atrophy, which made it difficult to slow its progression and try to preserve remaining vision. In February 2023, though, the U.S. Food and Drug Administration approved pegcetacoplan (Syfovre), a drug that can be injected directly into the eye to curb how quickly GA progresses, marking a significant change in the management of the disease for some people. Since then, another injection medication, avacincaptad pegol (Izervay) has also been approved.
Because early diagnosis is crucial to managing AMD and reducing your risk of GA, it’s important to know the signs and symptoms to watch out for:
1. Small Distortions in Your Vision
At first, there may be small areas in your vision that appear blurry, says Nora Lad, MD, PhD, an ophthalmologist and retinal specialist with Duke Health in Morrisville, North Carolina. The damage begins at the periphery of your macula and then moves toward the center. So, initially, you may have what Dr. Lad describes as patchy, piece-y, or blurry blind spots.
This symptom itself can be problematic. Because you may keep the center part of your vision and see relatively well, there may be delays in diagnosis, according to the Macular Degeneration Association.
2. Trouble Seeing in Dim Light
3. Blurred Faces
“As the disease progresses, blind spots enlarge and coalesce closer to the center of the macula … so you may have trouble seeing faces,” says Lad. An estimated 63 percent of people with geographic atrophy reported difficulty recognizing faces, according to a review.
4. Faded Colors
5. Wavy Lines
Be on the lookout for any changes in your vision, so you can tell your eye doctor sooner rather than later. You should also go in for a comprehensive eye exam on a regular basis.
Although there is no treatment for early dry AMD, intermediate-stage dry AMD can be treated with specific dietary supplements. And late-stage AMD, including geographic atrophy, can now be treated with eye injections.
The Takeaway
Geographic atrophy is an advanced form of dry AMD that is a common cause of vision loss in older people. Early diagnosis is crucial to helping preserve your vision if you develop geographic atrophy. Staying vigilant about signs and symptoms of worsening eye disease and getting treatment for AMD can reduce your risk of geographic atrophy.
- Age-Related Macular Degeneration. MedlinePlus. October 4, 2021.
- Rajanala K et al. Geographic Atrophy: Pathophysiology and Current Therapeutic Strategies. Frontiers in Ophthalmology. December 4, 2023.
- Fleckenstein M et al. Age-Related Macular Degeneration: A Review. JAMA. January 9, 2024.
- What Is Geographic Atrophy? Macular Degeneration Association.
- Bakri SJ et al. Geographic Atrophy: Mechanism of Disease, Pathophysiology, and Role of the Complement System. Journal of Managed Care & Specialty Pharmacy. May 1, 2023.
- Adult Vision: 41 to 60 Years of Age. American Optometric Association.
- Fleckenstein M et al. The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration. Ophthalmology. March 2018.
- Color Vision Deficiency. American Optometric Association.
- Age-Related Macular Degeneration (AMD). National Eye Institute. June 22, 2021.
- Geographic Atrophy (GA). Prevent Blindness.
- Boyd K. Have AMD? Save Your Sight With an Amsler Grid. American Academy of Ophthalmology. May 3, 2023.

Brittni Scruggs, MD, PhD
Medical Reviewer
Brittni Scruggs, MD, PhD, is an adult and pediatric vitreoretinal surgeon at Mayo Clinic in Rochester, Minnesota. In addition to her clinical practice, Dr. Scruggs teaches medical students, graduate students, residents, and fellows, and she participates in several clinical trials for inherited retinal diseases. As one of the principal investigators in the Mayo Retinal Regenerative Medicine Laboratory, Scruggs focuses on the optimization of gene therapy and cell-based therapy for improved safety and efficacy in patients with retinal degeneration. She is a member of the Mayo Gene Therapy Working Group.

Jessica Migala
Author
Jessica Migala is a freelance writer with over 15 years of experience, specializing in health, nutrition, fitness, and beauty. She has written extensively about vision care, diabetes, dermatology, gastrointestinal health, cardiovascular health, cancer, pregnancy, and gynecology. She was previously an assistant editor at Prevention where she wrote monthly science-based beauty news items and feature stories.
She has contributed to more than 40 print and digital publications, including Cosmopolitan, O:The Oprah Magazine, Real Simple, Woman’s Day, Women’s Health, Fitness, Family Circle, Health, Prevention, Self, VICE, and more. Migala lives in the Chicago suburbs with her husband, two young boys, rescue beagle, and 15 fish. When not reporting, she likes running, bike rides, and a glass of wine (in moderation, of course).